TUFRAFT

TUFRAFT is an alginate-based raft-forming antireflux formulation — a mechanistically unique non-pharmacological approach to GORD management that works through physical barrier formation rather than acid suppression.

Sodium Alginate 250mg per 5mL: Sodium alginate is a naturally derived polysaccharide (from brown seaweed) that reacts with gastric acid upon administration to form an insoluble alginic acid gel. This gel floats on the surface of the gastric contents — forming a low-density viscous "raft" that physically occupies the gastroesophageal junction and the proximal stomach immediately below the lower oesophageal sphincter (LOS). This alginate raft acts as a mechanical barrier that prevents acidic gastric contents from refluxing into the oesophagus, trapping the raft of gel at the acid-pocket zone (the area of high acid concentration just below the LOS that is the primary source of post-prandial refluxate).

Sodium Bicarbonate 133.5mg per 5mL: Serves a dual purpose — it reacts with sodium alginate in the presence of gastric acid to produce CO₂ bubbles that become entrapped within the alginate gel, reducing the gel density and ensuring it floats at the gastric surface as a buoyant raft. It also provides mild transient acid neutralisation during raft formation.

Calcium Carbonate per 5mL: Cross-links the alginate chains through divalent calcium-alginate interaction, increasing the structural rigidity and durability of the alginate raft. The firmer the raft, the longer it persists intact at the gastric surface and the more effective it is as a reflux barrier. Calcium carbonate also provides additional acid-neutralising buffer activity.

TUFRAFT is indicated for GORD and reflux-related conditions where physical prevention of acid contact with the oesophageal mucosa — rather than acid suppression — is the therapeutic goal.

GORD and Reflux Oesophagitis: The post-prandial alginate raft physically prevents acid reflux from reaching the oesophagus for 3–4 hours after administration — the period of maximum reflux risk following meals. Used as standalone therapy for mild-moderate GORD or as adjunct to PPI therapy for breakthrough post-prandial reflux symptoms.

Laryngopharyngeal Reflux (LPR): The alginate raft acts highest in the stomach — directly at the LOS — providing particular benefit for LPR where even small amounts of reflux reaching the laryngopharynx cause symptoms. ENT specialists use alginate for chronic laryngitis, throat clearing, and globus sensation from LPR.

Pregnancy GORD: PPIs have limited evidence in pregnancy, particularly first trimester — alginate formulations are considered safe in all trimesters and are recommended as first-line GORD therapy in pregnancy by major obstetric guidelines.

Post-Prandial Heartburn: On-demand use 20–30 minutes after meals, when reflux risk is highest.

Paediatric GORD: Alginate formulations are safe from infancy — used for infant regurgitation and GORD where the physical raft prevents reflux without systemic drug exposure.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.